Tailoring drug doses to fight Hard-to-Treat cancers
NCT ID NCT01552356
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This study tests whether adjusting the dose of the drug pazopanib based on each person's blood levels can improve treatment for advanced solid tumors that have spread or stopped responding to standard therapy. About 54 adults with these cancers will receive pazopanib, and researchers will monitor side effects, drug levels in the blood, and tumor response. The goal is to find the best dose that controls the disease while minimizing toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.